Nanhui Wu

Nanhui Wu

Auto-generated profile, based on publicly available information

Nanhui Wu

Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2022 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
DSDan-Dan Shan
Dan-Dan Shan
NWN. Wu
N. Wu
QWQ. Wang
Q. Wang
WRW. Ren
W. Ren
AZA. Zhu
A. Zhu
HXH. Xu
H. Xu

17 January 2022 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
MXMingyuan Xu
Mingyuan Xu
NWNanhui Wu
Nanhui Wu
QDQian Du
Qian Du
ZZZhiyu Zhou
Zhiyu Zhou
DDDan Deng
Dan Deng
YLYeqiang Liu
Yeqiang Liu

1 August 2025 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
JLJie Li
Jie Li
MXMingyuan Xu
Mingyuan Xu
NWNanhui Wu
Nanhui Wu
FWFei Wu
Fei Wu
JCJiashe Chen
Jiashe Chen
YLYeqiang Liu
Yeqiang Liu
Background: Diosmetin (DIOS) is a naturally abundant flavonoid and possesses various biological activities that hold promise as an anti-cancer agent. However, the anti-cancer activities and underlying mechanism of DIOS on cutaneous melanoma remain unclear. Objective: This study seeks to explore the anti-tumor effect and mechanism of DIOS in cutaneous melanoma. Methods: Here, a variety of in vitro and in vivo experiments, combined with RNA sequencing (RNA-seq), were employed to ascertain the potential anti-cutaneous melanoma capacity and mechanism of DIOS. Results: The results demonstrated that DIOS considerably impeded cell proliferation and triggered cell apoptosis in a dose- and time-dependent manner. Concurrently, DIOS markedly elevated the expression of pro-apoptotic proteins (Cleaved caspase-3, Bax, Cleaved PARP, and Cleaved caspase-9) and downregulated the expression of Bcl-2. Additionally, DIOS markedly upregulated the protein expressions of LC3B-II and Atg5, while downregulating p62 protein expression. Notably, pre-treatment with an autophagy inhibitor significantly inhibited DIOSinduced cell apoptosis and autophagy. Mechanistically, DIOS was identified to repress the PI3K/Akt/mTOR signaling pathway by western blot analyses and RNA-seq. Finally, in vivo experiments using a syngeneic mouse model confirmed the anti-tumor effect of DIOS, which exhibited high levels of apoptosis and autophagy. Conclusion: These findings propose that DIOS acts as a potential melanoma therapy that exerts its anti-tumor effects by triggering apoptosis and autophagy via inhibition of the PI3K/Akt/mTOR pathway.

1 April 2024 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
YHYimin He
Yimin He
MXMingyuan Xu
Mingyuan Xu
NWNanhui Wu
Nanhui Wu
FWFei Wu
Fei Wu
CLChangchang Li
Changchang Li
YLYeqiang Liu
Yeqiang Liu